Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Life Sciences will make remdesivir for distribution in countries that “face significant obstacles to healthcare access,” Gilead said.
The deal will be royalty-free until the World Health Organization says COVID-19 is no longer a global health crisis or another pharmaceutical product besides remdesivir or a vaccine is approved to treat or prevent COVID-19.
Remdesivir was granted emergency use authorization by the FDA May 1 after it was shown to shorten the recovery time of some COVID-19 patients in preliminary studies.
Read the full news release here.
More articles on pharmacy:
HHS unveils plan to distribute Gilead’s COVID-19 drug
Two-thirds of hospital pharmacies have reduced staff during COVID-19 pandemic, ASHP survey finds
New CMS rule could raise out-of-pocket drug costs
